XTNT XTANT MED HLDGS INC revenue, earnings and financials

For the quarter ended June 30, 2026, XTANT MED HLDGS INC reported revenue of $23.0M (down 35.0% from a year earlier), net income of −$9.41M and diluted EPS of −$0.07; over the last four quarters revenue was $110M and net income −$16.1M; for the fiscal year ended December 2025 revenue was $134M, up 14.2% on the year before.

XTNT annual revenue and earnings

• Fiscal year ended Dec 2025: revenue $134M, gross profit $84.3M, operating income $7.28M, net income $4.97K (margin 0.0%), EPS $0.03
• Fiscal year ended Dec 2024: revenue $117M, gross profit $68.2M, operating income −$12.1M, net income −$16.4K (margin 0.0%), EPS −$0.12
• Fiscal year ended Dec 2023: revenue $91.3M, gross profit $55.5M, operating income −$10.2M, net income $660 (margin 0.0%), EPS $0.01
• Fiscal year ended Dec 2022: revenue $58.0M, gross profit $32.1M, operating income −$6.76M, net income −$8.49M (margin -14.6%), EPS −$0.09
• Fiscal year ended Dec 2021: revenue $55.3M, gross profit $32.5M, operating income −$3.85M, net income −$4.85M (margin -8.8%), EPS −$0.06

XTNT quarterly revenue and earnings

• Quarter ended Jun 30, 2026: revenue $23.0M (down 35.0% year over year), net income −$9.41M, EPS −$0.07
• Quarter ended Mar 31, 2026: revenue $20.9M (down 36.5% year over year), net income −$3.09M, EPS −$0.02
• Quarter ended Dec 31, 2025 (from the annual report): revenue $32.4M (up 2.7% year over year), net income −$4.91M, EPS $0.00
• Quarter ended Sep 30, 2025: revenue $33.3M (up 19.0% year over year), net income $1.31M, EPS $0.01
• Quarter ended Jun 30, 2025: revenue $35.4M (up 18.3% year over year), net income $3.55M, EPS $0.02
• Quarter ended Mar 31, 2025: revenue $32.9M (up 18.0% year over year), net income $58.0K, EPS $0.00
• Quarter ended Dec 31, 2024 (from the annual report): revenue $31.5M (up 12.1% year over year), net income $13.3M, EPS −$0.02
• Quarter ended Sep 30, 2024: revenue $27.9M (up 11.7% year over year), net income −$5.02M, EPS −$0.04
• Quarter ended Jun 30, 2024: revenue $29.9M (up 48.0% year over year), net income −$3.86M, EPS −$0.03
• Quarter ended Mar 31, 2024: revenue $27.9M (up 55.3% year over year), net income −$4.40M, EPS −$0.03
• Quarter ended Dec 31, 2023 (from the annual report): revenue $28.1M (up 84.1% year over year), net income −$4.96M, EPS −$0.02
• Quarter ended Sep 30, 2023: revenue $25.0M (up 73.0% year over year), net income $9.23M, EPS $0.07
• Quarter ended Jun 30, 2023: revenue $20.2M (up 32.4% year over year), net income −$2.19M, EPS −$0.02
• Quarter ended Mar 31, 2023: revenue $17.9M (up 38.5% year over year), net income −$2.08M, EPS −$0.02
• Quarter ended Dec 31, 2022 (from the annual report): revenue $15.3M (up 9.3% year over year), net income −$2.21M, EPS −$0.01
• Quarter ended Sep 30, 2022: revenue $14.5M (up 5.0% year over year), net income −$2.35M, EPS −$0.03
• Quarter ended Jun 30, 2022: revenue $15.3M (up 2.0% year over year), net income −$1.71M, EPS −$0.02
• Quarter ended Mar 31, 2022: revenue $13.0M (up 3.3% year over year), net income −$2.21M, EPS −$0.03
• Quarter ended Dec 31, 2021 (from the annual report): revenue $14.0M, net income −$2.28M, EPS −$0.03
• Quarter ended Sep 30, 2021: revenue $13.8M, net income −$1.80M, EPS −$0.02

XTNT cash flow, buybacks and dividends

• Fiscal year ended Dec 2025: operating cash flow $12.5M, share buybacks n/a
• Fiscal year ended Dec 2024: operating cash flow −$11.9M, share buybacks n/a
• Fiscal year ended Dec 2023: operating cash flow −$9.52M, share buybacks n/a
• Fiscal year ended Dec 2022: operating cash flow −$5.34M, share buybacks n/a
• Fiscal year ended Dec 2021: operating cash flow $439K, share buybacks n/a

XTNT balance sheet

• Jun 30, 2026: cash $9.87M, total assets $79.7M, total liabilities $39.7M, shareholders' equity $40.0M, long-term debt $7.29M
• Mar 31, 2026: cash $12.1M, total assets $78.0M, total liabilities $29.4M, shareholders' equity $48.6M, long-term debt $8.10M
• Dec 31, 2025: cash $17.1M, total assets $94.1M, total liabilities $43.2M, shareholders' equity $51.0M, long-term debt $11.0M
• Sep 30, 2025: cash $10.4M, total assets $106M, total liabilities $55.9M, shareholders' equity $50.4M, long-term debt $17.4M
• Jun 30, 2025: cash $6.92M, total assets $103M, total liabilities $55.0M, shareholders' equity $48.5M, long-term debt $22.3M
• Mar 31, 2025: cash $5.03M, total assets $95.8M, total liabilities $52.0M, shareholders' equity $43.9M, long-term debt $22.2M
• Dec 31, 2024: cash $6.20M, total assets $93.8M, total liabilities $50.9M, shareholders' equity $43.0M, long-term debt $22.0M
• Sep 30, 2024: cash $6.60M, total assets $98.9M, total liabilities $53.2M, shareholders' equity $45.7M, long-term debt $19.1M

What is XTNT's revenue?

XTANT MED HLDGS INC reported $110M of revenue over its last four quarters, through June 30, 2026.

Is XTNT profitable?

No. XTANT MED HLDGS INC lost $16.1M over the last four quarters.

What is XTNT's EPS?

Diluted earnings per share over the last four quarters were −$0.08; −$0.07 in the latest quarter.

XTNT ownership and insider trades · All stocks